SENT012

SENT012 is an investigational gene therapy candidate currently in preclinical development for the treatment of osteoarthritis. Developed by Sentio BioSciences, the therapy utilizes an adeno-associated virus (AAV) vector platform designed for local, intra-articular delivery directly into the affected joint. The program aims to provide long-term therapeutic protein expression to modulate the joint environment, potentially slowing disease progression or providing durable symptomatic relief. While the specific transgene for SENT012 has not been publicly detailed in official pipeline disclosures, it is part of a suite of AAV-based musculoskeletal therapies being developed by the company to address the underlying pathophysiology of joint disease.